エピソード

  • 12: Monotherapies for Treatment of High-Risk Biochemical Recurrent Prostate Cancer

    12: Monotherapies for Treatment of High-Risk Biochemical Recurrent Prostate Cancer
    2026/04/01
    The faculty discusses how ARPI monotherapy may fit into the management of high-risk biochemically recurrent prostate cancer, with a focus on patient selection, trade-offs of monotherapy versus combination therapy, and practical counseling around efficacy, quality of life, and adverse events. The conversation also explores emerging questions around biomarkers, PARP inhibitors, treatment intensification, and how monotherapy may evolve as a therapeutic option in select patients.
    続きを読む 一部表示
    29 分
  • 11: Treatment Strategies with Androgen Receptor Pathway Inhibitors in Castration-Sensitive Prostate Cancer

    11: Treatment Strategies with Androgen Receptor Pathway Inhibitors in Castration-Sensitive Prostate Cancer
    2026/04/01
    The faculty discuss how androgen receptor pathway inhibitor–based strategies are reshaping the management of high-risk biochemical recurrence, with an emphasis on risk stratification, imaging, and patient selection for systemic therapy. The conversation also explores how long-term clinical evidence, treatment suspension, and emerging study designs are informing more individualized treatment decisions in practice.
    続きを読む 一部表示
    35 分
  • 7: Test File

    7: Test File
    2026/03/18
    33 分
  • 6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice

    6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice
    2025/12/03
    Panelists discuss how the recent FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC) expands treatment options, offering improved tolerability with lower fatigue rates and fewer central nervous system adverse effects than other androgen pathway inhibitors, while exploring considerations for patient selection, trial design interpretation, and the evolving role of real-world evidence in clinical decision-making.
    続きを読む 一部表示
    39 分
  • 4: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC

    4: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC
    2025/10/15
    This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.
    続きを読む 一部表示
    1 時間 3 分
  • 3: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC

    3: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC
    2025/10/15
    1 時間 3 分
  • 2: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC

    2: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC
    2025/10/15
    This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.
    続きを読む 一部表示
    1 時間 3 分
  • 1: Redefining Response in mHSPC: Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care

    1: Redefining Response in mHSPC: Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care
    2025/10/01
    Jack R. Andrews, MD; Alicia Morgans, MD, MPH; and Murilo de Almeida Luz, MD, discuss how ultralow prostate-specific antigen thresholds (below 0.02) serve as important prognostic biomarkers in metastatic hormone-sensitive prostate cancer, with recent post hoc analyses from the ARANOTE trial showing that patients achieving these ultralow levels with combination androgen deprivation therapy plus darolutamide therapy have significantly better radiographic progression-free survival and time to castration-resistant disease compared with those who don't reach these thresholds.
    続きを読む 一部表示
    31 分